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Olanzapine attenuates cue-elicited craving for tobacco

Abstract Rationale: Recent biological conceptualizations of craving and addiction have implicated mesolimbic
dopamine activity as a central feature of the process of
addiction. Imaging, and pharmacological studies have
supported a role for dopaminergic structures in cue-elicited
craving for tobacco. Objective: If mesolimbic dopamine activity is associated with cue-elicited craving for
tobacco, a dopamine antagonist should attenuate cueelicited craving for tobacco. Thus, the aim of the present
study was to determine whether an atypical antipsychotic
(olanzapine, 5 mg) decreased cue-elicited craving for
tobacco. Method: Participants were randomly assigned
to 5 days of pretreatment with olanzapine (5 mg; n=31) or
were randomly assigned to 5 days of a matching placebo
(n=28). Approximately 8 h after the last dose, participants
were exposed to a control cue (pencil) followed by
exposure to smoking cues. Participants subsequently
smoked either nicotine cigarettes or de-nicotinized cigarettes. Results: Olanzapine attenuated cue-elicited craving for tobacco but did not moderate the subjective effects
of smoking. Discussion: This study represents one of
the first investigations of the effect of atypical antipsychotics on cue-elicited craving for tobacco. The results
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suggest that medications with similar profiles may reduce
cue-elicited craving, which in turn, may partially explain
recent observations that atypical antipsychotics may
reduce substance use.
Keywords Smoking . Nicotine . Craving . Olanzapine

Introduction
There have been a number of new developments in
smoking cessation research over the past decade, including
the development of new pharmacological interventions
(e.g. buproprion) as well as the refinement of existing
behavioral and pharmacological interventions (e.g. nicotine replacement; see Niaura and Abrams 2002). Despite
these new developments, the overall cessation success rate
remains stagnant, suggesting that available treatments are
only modestly effective for today’s smokers. The lack of
significant progress with respect to the success of smoking
cessation interventions suggests that efforts to develop and
test new interventions should be reinvigorated and that
these efforts should be grounded in research on specific
mechanisms that play an important role in the etiology of
tobacco dependence and individual differences in the
expression of these mechanisms.
Although there has been some debate over the definition
of craving and its clinical relevance (see Tiffany 1995;
Sayette et al. 2000), cue-elicited craving for tobacco is a
construct that represents a useful laboratory target for
intervention development (Hutchison et al. 2002). A
number of studies have indicated that exposure to smoking
cues (e.g. the sight and smell of a lit cigarette) markedly
increases craving for tobacco (Niaura et al. 1988, 1992,
1998; Carter and Tiffany 1999; Hutchison et al. 1999;
Tiffany et al. 2000; Sayette et al. 2001). In addition, cueelicited craving for tobacco has been associated with
relapse (Shiffman et al. 1996) and has been the focus of
psychosocial and pharmacological intervention efforts
(Goldstein 1999; Hutchison et al. 1999; Shiffman et al.
2000a,b; Durcan et al. 2002), although others have

suggested that its clinical relevance is questionable
(Tiffany 1990, 1995).
At a biological level, craving has been linked to the
actions of drugs on the mesolimbic dopamine pathway in
the brain, and this substrate is thought to be an important
mechanism in the etiology of tobacco and drug dependence (Wise 1988; Robinson and Berridge 1993; Berridge
and Robinson 1998). Formally known as an incentive
sensitization model of craving, this conceptualization
suggests that repeated activation of the mesolimbic
dopamine pathway produces the progressive attribution
of incentive salience that is associated with neural
representations of drug related stimuli, thus creating the
motivational and appetitive properties of dependence that
is sometimes described as “craving.” The expression of
this incentive salience or craving can be subsequently
precipitated by cues associated with drug use. Consistent
with the animal literature, a recent study indicated that
exposure to smoking cues produced a hemodynamic
response in some of these same brain regions in humans
(e.g. the ventral tegmental area; Due et al. 2002).
Given the importance of dopamine in terms of the
attribution of incentive salience and expression of craving,
pharmacological interventions that target the dopamine
system could regulate craving, and by extension, drug
taking behavior. However, some research has suggested
that dopamine antagonists (e.g. haloperidol) may increase
smoking in both normal (Dawe et al. 1995; Caskey et al.
1999, 2002) and schizophrenic individuals (McEvoy et al.
1995a), while dopamine antagonists may decrease smoking behavior (Caskey et al. 1999, 2002). Increased
cigarette consumption in these individuals may be a
compensatory behavior due to a loss in the rewarding
value of nicotine or an effort to offset some of the negative
side effects of haloperidol (e.g. sedation, confusion, motor
dysfunction). In contrast, a recent study indicated that
haloperidol decreased the consumption of both nicotine
and de-nicotinized cigarettes (Brauer et al. 2001), and
studies with atypical antipsychotics (e.g. clozapine) have
suggested that these medications may reduce smoking and
substance use more generally (McEvoy et al. 1995a,b;
Green et al. 1999). The data from the study by Brauer et al.
(2001) are consistent with the premise that dopamine
antagonists might decrease cue-elicited craving for tobacco. On a related note, recent studies have suggested that
olanzapine, an atypical antipsychotic that has a better side
effect profile than traditional antipsychotic medications,
reduced cue-elicited craving for alcohol (Hutchison et al.
2003). Given the contradictory findings with tobacco use,
Table 1 Subject characteristics

a
Standard deviations appear in
parentheses next to the means of
continuous variables.

the question of whether pharmacotherapies that target
dopamine receptors will prove to be beneficial remains
unanswered.
The objective of the present study was to determine
whether olanzapine decreases cue-induced craving and
subsequent cigarette consumption. Because our previous
work has suggested that olanzapine reduces cue-elicited
craving for alcohol (Hutchison et al. 2003) and because
clinical reports suggest that olanzapine reduces substance
use (Lee et al. 1998; Green et al. 1999; Drake et al. 2000;
Zimmet et al. 2000) and smoking behavior among
schizophrenics (George et al. 2000), the present study
tested the effect of olanzapine on cue-elicited craving for
tobacco and subjective responses to nicotine administration. It was postulated that olanzapine would reduce cueelicited craving for tobacco while having no significant
effect on the rewarding effects of nicotine consumption. If
dopamine receptors mediate the effect of smoking cues,
we would expect olanzapine to attenuate craving relative
to the inactive control medication.

Materials and methods
Participants
The study was approved by the University of Colorado
Human Research Committee. All female subjects tested
negative for pregnancy prior to participation, all subjects
were required to have a breath alcohol level of zero before
each session, and all subjects were required to be in
excellent health as indicated by a thorough medical
screening (e.g. medical exam, CBC, EKG, LFTs) to
ensure that there were no contraindications for the use of
the study medications. The research participants were
screened medically at the University of Colorado General
Clinical Research Center in Boulder. Of the 82 individuals
who were initially enrolled into the study, 16 did not
complete the study (eight in the olanzapine condition and
eight in the placebo condition). In addition, six participants had a baseline CO less than 5 ppm and were
excluded, leaving a final sample of 59 participants who
completed both experimental sessions. The ethnic composition of the sample was 92% Caucasian, 3% AfricanAmerican, 2% Asian, and 3% Hispanic. Table 1 provides
the means and standard deviations for each medication
group on a number of demographic and smoking history
variables. t-Tests were used to confirm that the medication
groups did not differ on these variables (P>0.05).

Variablea

Placebo (n=28)

Olanzapine (n=31)

Age
Average no. cigarettes/day
Fagerstrom tolerance questionnaire
Baseline expired CO (ppm)
Baseline CO on nicotine day
Baseline CO on low nicotine day

20.6 (3.9)
15.2 (7.0)
2.4 (1.6)
16.9 (10.4)
8.6 (4.5)
10.5 (8.0)

22.3 (4.1)
15.6 (4.5)
2.6 (1.5)
17.6 (11.2)
10.3 (4.5)
10.8 (4.7)

Medication administration procedures
Volunteers were randomly assigned to receive either
olanzapine (5 mg) or a placebo. Thirty-one participants
(18 men, 13 women) received olanzapine and 28 (16 men,
12 women) received the placebo. The participants and the
experimenter were blind to the medication condition.
Participants were instructed to take five consecutive daily
doses of the study medication prior to each of two
experimental sessions scheduled 1 week apart. The first
four doses were to be taken a few hours before bedtime to
diminish the impact of any drowsiness experienced as a
result of olanzapine. The last dose was taken 8 h before
each of the experimental sessions. After taking each dose
of medication, participants called the laboratory to confirm
the time and date on which they took their dose. The
medications were packed into an opaque capsule with
50 mg riboflavin, which is detectable in urine under
ultraviolet light (Del Boca et al. 1996). In order to confirm
that participants had taken the medication the night before
the experimental session, a urine sample was collected in
the morning of the experimental session and tested for
riboflavin content under ultraviolet light. All of the
participants took the medication as directed. At the end
of each experimental session, participants were asked if
they thought they had received olanzapine or the placebo
in order to test the blind.
Procedure
Participants were scheduled for one baseline and two
experimental sessions, approximately 1 week apart.
Participants were instructed not to drink alcohol for
24 h, consume caffeine for 2 h, or to smoke for 8 h before
arriving at the laboratory. Participants attended the baseline session, where they signed consent forms and
completed questionnaires (see “Individual difference
measures” below). Participants were scheduled for the
first of the two experimental sessions 1 week later.
Participants received three nicotine cigarettes during one
of the experimental sessions and three de-nicotinized
cigarettes during the other experimental session in a
crossover design. Participants smoked either three nicotine
(1.1 mg) cigarettes separated by 25 min or smoked three
de-nicotinized cigarettes containing trace amounts of
nicotine (0.07 mg) separated by 25 min (for description
of research cigarettes; see Pickworth et al. 1999). The
inter-cigarette interval was designed to allow the participants enough time to complete measures and relax
between each cigarette. The de-nicotinized cigarettes
were used in order to control for CO and tar content as
well as the physical action of smoking. The de-nicotinized
cigarettes were not expected to deliver a psychoactive dose
of nicotine (Pickworth et al. 1999). After smoking each
cigarette, the participants completed subjective measures
of craving and smoking satisfaction and affect (see
“Experimental session measures” below).

The order of the two sessions was counterbalanced
across participants such that half of the participants
smoked the nicotine cigarettes on the first session and
half of the participants smoked the de-nicotinized cigarettes on the first session. Participants smoked the cigarettes
following standardized audio-taped instructions. Individuals were required to inhale from the cigarette for a count
of 2 s, then hold the smoke in their lungs for a count of 3 s,
and then asked to exhale and wait for 20 s, such that each
individual received 12 puffs from each cigarette over the
course of 5 min. The puffing procedure was designed to
standardize nicotine consumption across participants,
consistent with previous studies (Hutchison et al. 2000).
All experimental sessions occurred in the morning (before
noon). Each of the two sessions was scheduled at the same
time for a given subject and baseline CO measures were
taken at the beginning of each of these sessions. The entire
session lasted approximately 4 h.
Participants completed a smoking cue reactivity assessment at the beginning of each of the experimental sessions.
Following previously published procedures (Sayette and
Hufford 1994; Hutchison et al. 1999), participants were
first exposed to control cues by asking them to hold a
pencil for 3 min. The exposure to the control cue was
followed by an assessment of craving and a 5-min interval
prior to exposure to the smoking cue. Exposure to the
smoking cue consisted of instructing the participants to
remove one of their preferred brand of cigarettes from a
pack and light it without putting it in their mouths by
holding it in the flame for several seconds. Participants
were then instructed to focus their attention on the lit
cigarette. Participants completed measures of craving,
attention, and affect before and after each exposure.
Individual difference measures
A demographics questionnaire was used to collect
information on age, sex, marital status, socioeconomic
status (SES), occupation, income, education, and race
before the first session.
A smoking history questionnaire was used to collect
information on frequency and quantity of tobacco use
prior to the study, number of previous quit attempts, age
when first cigarette was smoked, and number of years as a
regular smoker.
The Fagerstrom tolerance questionnaire (FTQ) was
used to collect information on the severity of nicotine
dependence.
Expired carbon monoxide (CO) was also collected prior
to each session using a Vitalograph CO monitor to verify
compliance with the abstinence instructions (i.e. expired
CO less than 10 ppm).
Experimental session measures
Craving measure The craving measure consisted of five
items that were rated on a scale of 0–100 and that were

averaged to form a craving scale (Shiffman et al. 2003).
The five items included “I crave a cigarette right now,” “I
have an urge for a cigarette,” “I have a desire for a
cigarette right now,” “If it were possible, I would smoke
now,” and “All I want right now is a cigarette.”
Cronbach’s alpha for the scale was greater than 0.90 in
previous studies, suggesting good internal consistency
(Hutchison et al. 2000; Shiffman et al. 2003).
Positive affect/negative affect scale (PANAS) This was
used to collect information on mood at the follow-up
visits. The PANAS is a reliable and valid measure of both
positive and negative affect with alphas of 0.84–0.90
(Watson et al. 1988).
Hedonic scale (HS) This measure assessed the hedonic
value of the cigarettes by asking each participant to rate
the cigarettes in terms of “enjoyable” and “satisfying” on a
scale from 0 (not at all) to 10 (extremely).
Sedation and stimulation The biphasic alcohol effects
scale (BAES) was used to collect information on changes
in self-reported sedation and stimulation after smoking.
The BAES has previously demonstrated reliability and
validity in investigations of the stimulatory and sedative
effects of alcohol (Martin et al. 1993) and for assessing
medication effects (Swift et al. 1994). The sedation and
stimulation subscales each consist of seven items rated
from 0 (least) to 10 (most).

Results
To assess the integrity of the blind, a χ2 test was
performed on the item asking participants to guess
which medication they received at the end of each
experimental session. The tests were non-significant
(P>0.05), suggesting that participants were unable to
distinguish between the placebo and olanzapine. Similar
tests were conducted on items asking participants to guess
whether they had smoked the nicotine cigarettes or denicotinized cigarettes. These tests were significant
(P<0.05), with 68% of the participants correctly identifying the de-nicotinized cigarettes and 70% of participants
correctly identifying the nicotine cigarettes. Olanzapine
had no effect on the ability of participants to correctly
identify the cigarettes (P>0.05).

The analyses revealed a significant main effect for cue
[F(1,57)=29.01, P<0.001], indicating that smoking cues
significantly increased craving. There was also a significant medication by cue interaction [F(1,57)=5.10,
P<0.05], such that olanzapine attenuated cue-elicited
craving. There were no other significant main or interaction effects and no effects involving session (P>0.05).
Given the overall medication by cue interaction and the
lack of an effect for session, the means were collapsed
across session and presented in Fig. 1.
Effects of smoking
To address the subjective effects of nicotine, a series of
3×2×2 ANOVAs were conducted where cigarette (first,
second, or third cigarette) was a three-level within-subjects
factor, nicotine (nicotine versus de-nicotinized) was a twolevel within-subjects factor, and medication (olanzapine
versus placebo) was a two-level between-subjects factor.
The dependent variables examined were the craving scale
score, positive affect, negative affect, and the hedonic
scale score.
Craving measure Analyses revealed a significant main
effect for nicotine [F(1,55)=18.48, P<0.001], such that
nicotine cigarettes decreased craving (see Fig. 2). There
was also a significant effect for cigarette [F(2,110)=35.54,
P<0.001], such that craving generally decreased across
cigarettes regardless of nicotine condition, suggesting that
placebo cigarettes also reduced craving. There were no
significant effects involving medication (P>0.05).
Positive affect There were no main or interaction effects
for medication (P>0.05). There was a main effect for
cigarette [F(2,110)=10.59, P<0.01], and a significant

Cue-elicited craving
To analyze reactivity to smoking cues, a 2×2×2 mixed
design analyses of variance (ANOVAs) were conducted on
the craving scale score, where type of cue (control cue
versus smoking cue) was a two-level, within-subjects
factor, session (first versus second experimental session)
was a two-level, within-subjects factor, and medication
(olanzapine or placebo) was a two-level between-subjects
factor.

Fig. 1 Means and standard errors for craving scores after exposure
to control cues and smoking cues collapsed across Session 1 and
Session 2. Analyses indicated a significant medication by cue
interaction (P<0.05) such that olanzapine decreased cue-elicited
craving for tobacco. Simple effects tests indicated that exposure to
smoking cues significantly increased craving in the placebo
condition (P<0.001). There was only a marginally significant
increase in the olanzapine condition (P=0.05)

Fig. 2 Means and standard
errors for craving scores after
smoking each cigarette. Analyses indicated a main effect for
nicotine, such that cigarettes
containing nicotine resulted in a
significantly lower craving as
compared to the control cigarettes (P<0.05). There were no
significant effects for medication

effect for nicotine [F(1,55)=4.92, P<0.05], such that
positive affect was increased across cigarettes and was
greater when participants received the nicotine cigarettes.
Negative affect Analyses revealed a significant effect for
cigarette [F(1,10)=3.68, P<0.05], such that negative affect
decreased across cigarettes. There were no other significant main effects or interactions (P>0.05).
Hedonic scale Analyses revealed a significant main effect
for nicotine [F(1,55)=44.97, P<0.001], such that the
nicotine cigarettes were much more rewarding than the
de-nicotinized cigarettes. There was also a significant
effect for cigarette [F(2,110)=22.16, P<0.001], such that
the hedonic value of the cigarettes generally decreased
across cigarettes. There were no significant effects
involving medication (P>0.05).
Sedation Analyses indicated a main effect for nicotine [F
(1,49)=4.63, P<0.05], such that the nicotine cigarettes
decreased sedation. There was also a main effect for
cigarette [F(2,98)=10.23, P<0.01], indicating that sedation
generally decreased across cigarettes. There were no main
or interaction effects involving medication (P>0.05),
suggesting that olanzapine did not produce significant
sedation.
Stimulation Analyses indicated a main effect for cigarette
[F(2,110)=8.91, P<0.01], indicating that stimulation generally increased across cigarettes. There were no main or
interaction effects involving medication (P>0.05) or
nicotine, suggesting that olanzapine and nicotine did not
produce significant changes in stimulation.

Discussion
The findings of the present study indicate that olanzapine
attenuates cue-elicited craving for tobacco but does not
influence the rewarding effects of smoking. From a
theoretical perspective, it is not surprising that olanzapine
reduces the appetitive value of alcohol and drug while
having minimal influence over the rewarding or hedonic
aspects of alcohol and drug use. One of the prominent
theories of addiction has suggested that mesolimbic

dopamine circuitry subserves the attribution of incentive
salience (i.e. “wanting”) rather than the hedonic aspects of
drug use behavior (i.e. “liking”; see Robinson and
Berridge 1993; Berridge and Robinson 1998). In addition,
these results are consistent with other recent studies that
have suggested that dopamine antagonists may reduce the
appetitive aspects of smoking behavior (Brauer et al.
2001) and studies that have suggested that olanzapine
reduces craving for alcohol (Hutchison et al. 2001).
Conversely, the findings of the present study contradict
theories of drug use behavior that emphasize the
importance of dopamine in terms of pleasure, reward,
and reinforcement and contradict recent studies suggesting
that dopamine antagonists decrease the rewarding aspects
of smoking, thereby increasing tobacco use (Caskey et al.
1999, 2002). These studies noted changes in smoking
topology after haloperidol treatment but did not detect any
changes on measures of positive mood. It is possible that
no changes in positive mood were observed because
dopamine antagonists do not have an effect on the positive
affect generated by smoking, consistent with the present
study. It is also possible that the assessment of mood was
not optimal for detecting an effect in the previous studies,
given that the assessment of mood occurred 30 min after
smoking.
Despite this preliminary work, it has yet to be
determined whether the effect of olanzapine on cueelicited craving for tobacco might translate into a reduction in tobacco use behavior. However, there is some
evidence to suggest that atypical antipsychotics may
produce decreases in tobacco use and craving. For
example, a recent smoking cessation trial in schizophrenics suggested that the combination of nicotine replacement therapy (NRT) and atypical antipsychotics were
more than twice as effective as NRT and typical
antipsychotics (George et al. 2000). The authors of the
study noted that olanzapine and risperidone were associated with the greatest success. Likewise, a comparison
between olanzapine and valproic acid in bipolar patients
indicated that olanzapine significantly reduced selfreported smoking. In addition, several studies have
suggested that atypical antipsychotics reduce alcohol and
drug use behavior in psychiatric patients (Lee et al. 1998;
Green et al. 1999; Drake et al. 2000; Zimmet et al. 2000).
However, it is not clear how these medications may

influence smoking behavior in non-psychiatric populations. Future studies will need to address this question.
It is also interesting to note that de-nicotinized cigarettes
reduced craving for cigarettes immediately after smoking,
as illustrated in the present study (Fig. 2) and in other
research (e.g. Butschky et al. 1995; Pickworth et al. 1999;
Brauer et al. 2001). Furthermore, results of the present
study illustrate that repeated administration of the denicotinized cigarettes continues to decrease cigarette
craving. These results extend the findings of Dallery et
al. (2003), where placebo cigarette smoking in a rapid
smoking or in a paced smoking paradigm, decreased urges
to smoke and smoking. The ability of the placebo
cigarettes to diminish urge to smoke has been attributed
to the stimulation of sensory cues associated with the
inhalation of tobacco smoke or from components of
tobacco smoke other than nicotine (Robinson et al. 2000).
It is interesting that olanzapine was evidently able to
diminish the cigarette craving induced by holding and
attending (but not smoking) a lit cigarette but unable to
diminish placebo cigarette-induced reduction in cravings.
These results tentatively suggest that the neural mechanisms responsible for cigarette craving and smoking urge
are heterogeneous and may be influenced by diverse
behavioral or pharmacological manipulations.
Several limitations of the present study need to be
addressed. The present study only used a single dose of
olanzapine. This dose was chosen for practical reasons.
Higher doses would have been impractical due to side
effects. In addition, previous studies have documented that
5 mg is sufficient for reducing cue-elicited craving for
alcohol (Hutchison et al.2001, 2003). Therefore, it is not
clear whether higher doses may actually reduce the
rewarding effects of smoking in humans. The addition of
an active medication that controls for activity at 5-HT2
receptors and the general sedative effects of olanzapine
(e.g. cyproheptadine) would also be useful in future
studies. The present study with olanzapine utilized a
placebo control which does not control for the effects of
olanzapine on 5-HT2 receptors, histamine receptors, and
the non-specific sedating effects of the medication. Thus,
expectancies regarding the effects of the medication and/or
the effects of the medication on 5-HT2 or histamine
receptors of the medication cannot be excluded as
explanations for the results. Given that other studies with
olanzapine have utilized active controls, future studies
should be able to resolve some of these interpretive issues.
Finally, the generalizeability of the results may be
somewhat limited, given that the present sample was
young with low nicotine dependence scores.
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